Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) traded up 2.4% during mid-day trading on Thursday . The company traded as high as $14.28 and last traded at $14.22, with a volume of 236,805 shares changing hands. The stock had previously closed at $13.88.

A number of equities research analysts have recently issued reports on the stock. Citigroup Inc. assumed coverage on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 2nd. They set a “buy” rating and a $21.00 price target for the company. Wedbush lifted their price target on shares of Lexicon Pharmaceuticals from $30.00 to $31.00 and gave the company an “outperform” rating in a research report on Friday, August 5th. Stifel Nicolaus lifted their price target on shares of Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, August 5th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 3rd. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, August 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. Lexicon Pharmaceuticals has an average rating of “Hold” and a consensus price target of $20.07.

The stock has a 50-day moving average of $15.48 and a 200 day moving average of $13.47. The company’s market capitalization is $1.49 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.04. The firm earned $20.10 million during the quarter, compared to analyst estimates of $12.36 million. During the same quarter in the prior year, the firm earned ($0.27) EPS. The business’s quarterly revenue was up 5186.8% compared to the same quarter last year. Analysts predict that Lexicon Pharmaceuticals Inc. will post ($1.54) earnings per share for the current fiscal year.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.